CY1119451T1 - Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο - Google Patents

Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο

Info

Publication number
CY1119451T1
CY1119451T1 CY20161101328T CY161101328T CY1119451T1 CY 1119451 T1 CY1119451 T1 CY 1119451T1 CY 20161101328 T CY20161101328 T CY 20161101328T CY 161101328 T CY161101328 T CY 161101328T CY 1119451 T1 CY1119451 T1 CY 1119451T1
Authority
CY
Cyprus
Prior art keywords
lif
antibodies
treatment
patients
lift
Prior art date
Application number
CY20161101328T
Other languages
English (en)
Inventor
Joan Seoane Suarez
Judit Anido Folgueira
Andrea Saez Borderias
Original Assignee
Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron (Vhio)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron (Vhio) filed Critical Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron (Vhio)
Publication of CY1119451T1 publication Critical patent/CY1119451T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5415—Leukaemia inhibitory factor [LIF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Radiology & Medical Imaging (AREA)

Abstract

Η εφεύρεση σχετίζεται με αντισώματα που κατευθύνονται έναντι του ανθρώπινου Ανασταλτικού Παράγοντα Λευχαιμίας (LIF) και μιας κυτταρικής σειράς υβριδώματος που παράγει τα εν λόγω αντισώματα. Η εφεύρεση σχετίζεται επίσης με μια μέθοδο για την παρεμπόδιση/αναστολή του πολλαπλασιασμού των βλαστικών κυττάρων και με μια in vitro μέθοδο για τη διάγνωση παθήσεων που σχετίζονται με ανεπιθύμητο κυτταρικό πολλαπλασιασμό σε ένα υποκείμενο ή τον προσδιορισμό της προδιάθεσης ενός υποκειμένου να πάσχει από την εν λόγω πάθηση που σχετίζεται με ανεπιθύμητο κυτταρικό πολλαπλασιασμό ή την πρόγνωση του μέσου προσδόκιμου ζωής ενός υποκειμένου που πάσχει από την εν λόγω πάθηση. Το θεραπευτικό δυναμικό των εν λόγω αντισωμάτων βασίζεται στην παρατήρηση ότι η αναστολή του LIF μπορεί να χρησιμοποιηθεί σε θεραπευτικές συνθέσεις για τη θεραπεία παθήσεων που σχετίζονται με ανεπιθύμητο πολλαπλασιασμό.
CY20161101328T 2010-04-05 2016-12-22 Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο CY1119451T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10380049A EP2371860A1 (en) 2010-04-05 2010-04-05 Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
EP11715676.0A EP2556091B1 (en) 2010-04-05 2011-04-05 Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
PCT/EP2011/055253 WO2011124566A1 (en) 2010-04-05 2011-04-05 Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation

Publications (1)

Publication Number Publication Date
CY1119451T1 true CY1119451T1 (el) 2018-03-07

Family

ID=42338260

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101328T CY1119451T1 (el) 2010-04-05 2016-12-22 Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο

Country Status (25)

Country Link
US (3) US8926956B2 (el)
EP (3) EP2371860A1 (el)
JP (2) JP6289906B2 (el)
KR (5) KR20170125137A (el)
CN (2) CN103797031A (el)
AU (1) AU2011237922B2 (el)
BR (1) BR112012025517B1 (el)
CA (1) CA2797257A1 (el)
CY (1) CY1119451T1 (el)
DK (1) DK2556091T3 (el)
EA (2) EA036698B9 (el)
ES (1) ES2608699T3 (el)
HK (3) HK1180702A1 (el)
HR (1) HRP20161736T1 (el)
HU (1) HUE030578T2 (el)
IL (3) IL222270A (el)
LT (1) LT2556091T (el)
MX (2) MX2012011636A (el)
PL (1) PL2556091T3 (el)
PT (1) PT2556091T (el)
RS (1) RS55539B1 (el)
SG (1) SG184429A1 (el)
SI (1) SI2556091T1 (el)
SM (1) SMT201600468T1 (el)
WO (1) WO2011124566A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598031A (en) * 2005-07-19 2013-11-29 Stemgen S P A Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2015040243A2 (en) * 2013-09-23 2015-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
TWI486172B (zh) * 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
CN106687134A (zh) * 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
WO2016154203A1 (en) 2015-03-23 2016-09-29 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
EP3555132B1 (en) * 2016-12-19 2023-11-15 Medimmune Limited Antibodies against lif and uses thereof
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
SG11202009966SA (en) * 2018-04-12 2020-11-27 Medimmune Ltd Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
SG11202011170YA (en) * 2018-05-14 2020-12-30 Medimmune Ltd Antibodies against lif and dosage forms thereof
KR20210024007A (ko) * 2018-06-18 2021-03-04 메디뮨 리미티드 암이 있는 개체에서 항-lif 항체 치료에 대한 반응을 개선하기 위한 방법
CN112955178A (zh) * 2018-06-18 2021-06-11 免疫医疗有限公司 用于治疗癌症的、lif抑制剂和基于铂的抗肿瘤剂的组合
WO2021057991A1 (zh) * 2019-09-29 2021-04-01 北京加科思新药研发有限公司 对lif具有特异性的结合分子及其用途
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
CN111378036B (zh) * 2020-01-09 2021-08-10 北京浩古元方生物医药科技有限公司 一种抗人白血病抑制因子单克隆抗体的制备方法及其应用
CN112294812B (zh) * 2020-11-18 2022-08-16 新乡医学院 一种小分子抑制剂在制备抗肿瘤药物方面的应用
CN114672460B (zh) * 2021-12-21 2023-06-23 中国人民解放军军事科学院军事医学研究院 一种靶向cd44的异质型cic细胞模型的制备方法及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB9004890D0 (en) 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
WO1993023556A1 (en) 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
AU4241693A (en) 1992-05-15 1993-12-13 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
MX9707939A (es) * 1995-04-24 1997-12-31 Genentech Inc Uso de antagonistas del factor inhibidor de la leucemia y la endotelina.
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1497445A2 (en) 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
US20060127902A1 (en) * 2002-08-15 2006-06-15 Genzyme Corporation Brain endothelial cell expression patterns
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005030803A1 (en) 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
JPWO2005116204A1 (ja) 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20110135645A1 (en) 2006-10-04 2011-06-09 The Scripps Research Institute Human antibodies neutralizing human metapneumovirus
CN101440128A (zh) * 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
WO2010054499A1 (en) * 2008-11-11 2010-05-20 Telefonaktiebolaget L M Ericsson (Publ) A dpd system with multiple transmitter paths
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥

Also Published As

Publication number Publication date
MX2012011636A (es) 2013-04-03
MX365054B (es) 2019-05-21
HK1180702A1 (zh) 2013-10-25
SMT201600468T1 (it) 2017-03-08
IL222270A0 (en) 2012-12-31
US10968273B2 (en) 2021-04-06
ES2608699T3 (es) 2017-04-12
EA202092276A2 (ru) 2021-01-29
EP2556091A1 (en) 2013-02-13
KR20200119344A (ko) 2020-10-19
DK2556091T3 (en) 2017-01-16
EA202092276A3 (ru) 2021-04-30
JP2013523796A (ja) 2013-06-17
KR20170125137A (ko) 2017-11-13
WO2011124566A1 (en) 2011-10-13
JP6483059B2 (ja) 2019-03-13
EA036698B1 (ru) 2020-12-09
SG184429A1 (en) 2012-11-29
AU2011237922A1 (en) 2012-11-01
IL241952A (en) 2017-10-31
EA036698B9 (ru) 2021-02-25
KR20130121679A (ko) 2013-11-06
HK1208469A1 (en) 2016-03-04
CN109320609A (zh) 2019-02-12
IL222270A (en) 2016-06-30
HUE030578T2 (en) 2017-06-28
IL254664A0 (en) 2017-11-30
HRP20161736T1 (hr) 2017-02-10
PL2556091T3 (pl) 2017-04-28
LT2556091T (lt) 2016-12-27
BR112012025517B1 (pt) 2021-08-31
JP2017019775A (ja) 2017-01-26
KR20190061098A (ko) 2019-06-04
IL254664B (en) 2022-03-01
US20130142808A1 (en) 2013-06-06
JP6289906B2 (ja) 2018-03-07
US20150139989A1 (en) 2015-05-21
SI2556091T1 (sl) 2017-02-28
BR112012025517A2 (pt) 2017-11-28
CA2797257A1 (en) 2011-10-13
KR20180078352A (ko) 2018-07-09
EP3045473A1 (en) 2016-07-20
EA201201373A1 (ru) 2013-04-30
AU2011237922B2 (en) 2014-07-10
EP2371860A1 (en) 2011-10-05
CN103797031A (zh) 2014-05-14
HK1223384A1 (zh) 2017-07-28
PT2556091T (pt) 2017-01-03
KR102294207B1 (ko) 2021-08-26
RS55539B1 (sr) 2017-05-31
US8926956B2 (en) 2015-01-06
US20190119373A1 (en) 2019-04-25
EP2556091B1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
CY1119451T1 (el) Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
CY1124148T1 (el) Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
CY1126122T1 (el) Αναστολεις πρωτεϊνικης φωσφατασης της τυροσινης
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
CY1119751T1 (el) Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3
CY1118551T1 (el) Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4
TR201904638T4 (tr) pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi.
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
CY1117604T1 (el) Μια νεα ομαδα αναστολεων του μονοπατιου stat3 και αναστολεων του μονοπατιου καρκινικων βλαστοκυτταρων
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
CY1121436T1 (el) Δοσολογια για τους αναστολεις των kinασων janus (jak)
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
CO2020004831A2 (es) Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
ECSP12012134A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
ECSP13012913A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
EA201792669A1 (ru) Igfbp3 и его применение
BR112018011224A2 (pt) processo de avaliação do risco de complicações nos pacientes que apresentam uma síndrome da resposta inflamatória sistêmica (sirs)
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?